文献速递免疫规划传染病防控与疫情报告

三价流感病毒神经氨酸酶与HCA2融合LTB(TT)鼻内初免-加强免疫研究

Intranasal prime-boost immunization with trivalent influenza virus neuraminidase proteins and conserved HCA2 sequences fused to a circularly permuted E. coli heat-labile enterotoxin B subunit.
PubMed 文献 · Vaccine · 2026-03-18

研究以杆状病毒-昆虫细胞系统表达三价重组NA蛋白(N1*、N2、BN),联合鼻内佐剂LTB(TT)-HCA2在小鼠中初免-加强免疫。虽对H1N1抗体应答有限,但三剂方案所有联合LTB(TT)-HCA2组在H1N1和H3N2攻击后完全保护并体重恢复;四剂方案对H7N9黏膜抗体弱且未能保护。

要点

  • 三价NA联合LTB(TT)-HCA2鼻内免疫对H3N2和B型流感抗体应答高于H1N1。
  • 三剂方案下联合LTB(TT)-HCA2组对H1N1和H3N2攻击完全保护并体重完全恢复。
  • 四剂方案对H7N9交叉血清抗体有诱导但黏膜抗体弱,未获保护。

核心结论

  • 靶向四聚体NA胞外域并结合鼻内递送、黏膜佐剂及保守HCA2序列,可作为通用流感疫苗的候选策略。

研究设计与样本

  • BALB/c小鼠经鼻内初免-加强免疫,比较三剂或四剂方案。
  • 抗原为重组四聚体NA蛋白N1*(含N329/K331T糖基化掩蔽突变)、N2和BN,佐剂为LTB(TT)或LTB(TT)-HCA2。

主要发现

  • 三剂方案中,10 μg每种NA加10 μg LTB(TT)或15 μg LTB(TT)-HCA2组对H3N2和B型流感的IgG、NAI及复制抑制抗体滴度高于H1N1。
  • 将N1*剂量增至15 μg未增强应答。
  • 三剂方案联合LTB(TT)-HCA2组虽H1N1抗体应答有限,但H1N1和H3N2攻击后完全保护且体重完全恢复。
  • 四剂方案联合LTB(TT)、LTB(TT)-HCA2或LTB(TT)-HCA2+poly I:C对H3N2和B型流感应答强于H1N1,H1N1攻击后100%存活且体重完全恢复。
  • 四剂方案诱导针对H7N9的交叉亚型血清抗体,但黏膜抗体较弱且未提供保护。

关键数值与推荐

  • 三剂方案:每只小鼠鼻内接种10 μg N1*、10 μg N2、10 μg BN,联合10 μg LTB(TT)或15 μg LTB(TT)-HCA2。
  • 四剂方案:三价NA抗原联合LTB(TT)、LTB(TT)-HCA2或LTB(TT)-HCA2+poly I:C。
  • N1*含N329/K331T糖基化掩蔽突变;HCA2序列为三个串联重复。

临床怎么用

  • 鼻内接种三价NA联合LTB(TT)-HCA2可在对H1N1抗体应答有限时仍对H1N1和H3N2攻击提供完全保护。
  • 增加N1*剂量至15 μg未增强抗体应答,提示剂量优化需考虑抗原特性。
  • 四剂方案对H7N9黏膜免疫弱,提示需进一步优化佐剂或递送策略以拓宽交叉保护。

局限性

  • 研究仅在小鼠模型中进行,尚未在人体验证。
  • 对H1N1的抗体应答有限,保护机制可能不完全依赖血清抗体。
  • 四剂方案对H7N9黏膜抗体弱且未保护,交叉保护范围有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To develop a mucosal influenza vaccine, we used trivalent recombinant neuraminidase (NA) proteins in combination with a circularly permuted TT mutant of the E. coli heat-labile enterotoxin B subunit, LTB(TT), as a mucosal adjuvant. Recombinant tetrameric NA proteins-N1* (with N329/K331T glycan-masking mutations), N2, and BN-were engineered using the tetramerization domains from either Staphylothermus marinus tetrabrachion or human vasodilator-stimulated phosphoprotein, and produced using baculovirus-insect cell expression system. To enhance immune responses, conserved HCA2 sequences with three tandem repeats were genetically fused to LTB(TT), expressed in E. coli, and co-administered intranasally with the trivalent NA proteins. BALB/c mice were immunized using either three- or four-dose prime-boost regimens. In the three-dose regimen, mice receiving 10 μg each of N1*, N2, and BN with 10 μg LTB(TT) or 15 μg LTB(TT)-HCA2 developed higher IgG, NA-inhibiting (NAI), and replication-inhibition antibody titers against H3N2 and influenza B compared to H1N1. Increasing the N1* dose to 15 μg did not enhance responses. Despite eliciting only modest antibody responses against H1N1, but high titers against H3N2 and influenza B viruses, all groups immunized with the trivalent NA formulation combined with LTB(TT)-HCA2 exhibited complete protection and full weight recovery following both H1N1 and H3N2 viral challenges. In the four-dose regimens, using combinations of trivalent NA antigens with LTB(TT), LTB(TT)-HCA2, or LTB(TT)-HCA2 + poly I:C elicited stronger responses to H3N2 and influenza B than to H1N1 viruses. Nonetheless, all immunized groups demonstrated 100% survival and full weight recovery following H1N1 virus challenge. Although the four-dose prime-boost immunization regimen induced cross-subtype serum antibody responses against H7N9, the corresponding mucosal antibody responses were relatively weak and failed to confer protective immunity. These findings support an alternative strategy to influenza vaccine development by targeting the tetrameric ectodomain of NA as a vaccine antigen, and incorporating intranasal delivery, mucosal adjuvants, and conserved HCA2 sequences to advance a potential universal influenza vaccine platform.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hung HC, Jheng KW, Cheng HY, et al. Intranasal prime-boost immunization with trivalent influenza virus neuraminidase proteins and conserved HCA2 sequences fused to a circularly permuted E. coli heat-labile enterotoxin B subunit. Vaccine. 2026. PMID: 41855645. doi:10.1016/j.vaccine.2026.128488

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。